Cancer medicine had an extraordinary weekend in Madrid.

At the European Society for Medical Oncology Congress, Amgen’s Imdelltra, added to AstraZeneca’s Imfinzi as maintenance therapy for extensive-stage small-cell lung cancer, cut the risk of death by 58%. Median survival rose from just under 13 months to a little over 21 months.

Recommended Stories

Trump is right to rebalance global drug prices

Same treatment, 30% less pay: Medicare’s new math will put cancer care out of reach

Pancreatic cancer had a 13% survival rate. Trump’s FDA just changed everything